- Home
- Products
- Customized ADCs
- IL6
- Anti-IL6 (Sirukumab)-MC-MMAF ADC
Anti-IL6 (Sirukumab)-MC-MMAF ADC (CAT#: ADC-W-1408)
This ADC product is comprised of an anti-IL6 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL6
- Alternative Names
- IL6; interleukin 6 (interferon, beta 2); IFNB2; interleukin-6; BSF2; HGF; HSF; IL 6; CDF; BSF-2; IFN-beta-2; interferon beta-2; interleukin BSF-2; hybridoma growth factor; CTL differentiation factor; B-cell stimulatory factor 2; B-cell differentiation factor; IL-6;
- Target Entrez Gene ID
- 3569
- Target UniProt ID
- P05231
- Overview
- This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including suspectibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. Alternative splicing results in multiple transcript variants.
- Overview
- Human Anti-IL6 IgG1-kappa antibody, Sirukumab
- Generic name
- Sirukumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL13 (Anrukinzumab)-SMCC-DM1 ADC (CAT#: ADC-W-1298)
- Anti-CD33 (Gemtuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-2538)
- Anti-E. coli Stx2A (Setoxaximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2485)
- Anti-OxLDL-SMCC-DM1 ADC (CAT#: ADC-W-2090)
- Anti-TNFRSF8-β-glucuronide-Camptothecin Analog ADC-14 (CAT#: ADC-W-349)
- Anti-CD2 (Siplizumab)-SPDB-DM4 ADC (CAT#: ADC-W-783)
- Anti-ERBB3 (Duligotuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2369)
- Anti-MUC1 (Sontuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-2487)
- Anti-IL5 (Reslizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1394)
- Anti-IL1B (Gevokizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1333)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1408. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2249 | Anti-IL6 (Enlimomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1434 | Anti-IL6-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1436 | Anti-IL6 (Elsilimomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1438 | Anti-IL6 (Elsilimomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2251 | Anti-IL6 (Enlimomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-322 | Anti-CD19-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
